Clinical Trials Logo

Clinical Trial Summary

To assess the safety, tolerability, and efficacy of QRX003 lotion (4%) when added to standard of care treatment regimen, including systemic therapy in subjects with Netherton syndrome


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05789056
Study type Interventional
Source Quoin Pharmaceuticals
Contact TI Clinical Research
Phone 858-571-1800
Email clinicalresearch@therapeuticsinc.com
Status Recruiting
Phase Phase 2/Phase 3
Start date March 14, 2023
Completion date December 30, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05979831 - A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome Phase 1/Phase 2
Completed NCT00208026 - Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome Phase 1/Phase 2
Completed NCT05583669 - A Study to Assess the Safety and Pharmacokinetics of Multiple Ascending Subcutaneous Doses of DS-2325a in Healthy Subjects Phase 1
Completed NCT01428297 - A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome Phase 1
Recruiting NCT05856526 - A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome Phase 2/Phase 3
Recruiting NCT05521438 - Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome Phase 2/Phase 3
Completed NCT05388903 - A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects Phase 1
Recruiting NCT06137157 - Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome Phase 1
Not yet recruiting NCT05902663 - Natural History of Netherton Syndrome
Recruiting NCT04244006 - A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome Phase 2/Phase 3
Recruiting NCT03417856 - Defining the Skin and Blood Biomarkers of Ichthyosis
Completed NCT02113904 - Clinical Trial Using Humira in Netherton Syndrome Phase 2
Recruiting NCT05211830 - A Study to Evaluate Topically Applied SXR1096 Cream in Patients With Netherton Syndrome Phase 1/Phase 2
Completed NCT03041038 - The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Phase 2
Recruiting NCT02081313 - Natural History and Biological Study of Netherton Syndrome N/A
Recruiting NCT01545323 - Gene Therapy for Netherton Syndrome Phase 1